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Abstract 
Background: Minimally invasive therapies, such as microwave ablation (MWA), are widely used for the treatment of 
solid tumors. Previous studies suggest that MWA is feasible for the treatment of small breast cancer, and thermal abla-
tion may induce adaptive antitumor immunity. However, the induced immune responses are mostly weak, and the 
immunomodulation effects of MWA in breast cancer are unclear. Immunostimulant OK-432 can induce tumor-specific 
T-cell responses and may augment the immunity induced by MWA.
Methods: We treated 4T1 breast cancer bearing BALB/c mice with MWA, OK-432, MWA plus OK-432, or left without 
treatment. Survival time was evaluated with the Kaplan–Meyer method comparing survival curves by log-rank test. 
On day 25 after ablation, surviving mice received tumor rechallenge, and the rechallenged tumor volumes were cal-
culated every 5 days. Immunohistochemistry and flow cytometry were used to evaluate the T-cell immune responses 
in ablated tissues and spleens. The tumor-specific immunity was assessed by enzyme-linked immunospot assays. 
Besides, the cytokine patterns were identified from enzyme-linked immunosorbent assay.
Results: Microwave ablation plus OK-432 resulted in longer survival than single treatment and protect most surviv-
ing mice from tumor rechallenge. Both local and systemic T-cell responses were induced by MWA and were further 
enhanced by subsequent administration of OK-432. Moreover, the combination of MWA and OK-432 induced stronger 
tumor-specific immune responses than MWA alone. In addition, OK-432 and MWA synergistically promoted the pro-
duction of Th1-type but not Th2-type cytokines, and polarized T-cell responses to Th1-dominant state.
Conclusions: The T-cell immune responses were activated by MWA in breast cancer. Furthermore, the combination 
of MWA and OK-432 induced Th1-type response and elicited specific antitumor immunity.
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Background
Microwave ablation (MWA) is a relatively new minimally 
invasive therapy that generates electromagnetic heating 
and causes focal hyperthermic injury to destroy tumor 
tissues [1]. MWA shows several advantages over radiofre-
quency ablation (RFA), the most commonly used thermal 
ablation technique [2–5], and has proven to be an effec-
tive and safe treatment option for liver, lung, and kid-
ney tumors [6]. Our group has previously reported that 
MWA is feasible for small breast cancer [7].
Tumor debris produced by thermal ablation provide 
pro-inflammatory signals and serve as tumor antigens 
to induce adaptive antitumor immunity [1, 8]. Recent 
study has reported that MWA of osteosarcoma can elicit 
tumor-specific T-cell immune response in a rat model 
[9]. T-cell immune responses induced by MWA have 
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the tumor recurrence rate after MWA is similar to that 
after curative surgical resection [11, 12]. These results 
indicate that the antitumor immunity induced by MWA 
is not strong enough to prevent the recurrence of can-
cers. Thus, additional immunomodulatory strategies are 
needed to enhance the antitumor immunity.
OK-432, a penicillin-inactivated and lyophilized prepa-
ration of a low-virulence strain Su of Streptococcuspyo-
genes (group A), was approved by Japan administration 
in 1975 as an immunotherapeutic agent in cancers [13]. 
Previous studies have reported OK-432 induce pro-
inflammatory cytokines to activate T-cell-mediated 
immunity [14, 15]. It has been reported that OK-432 aug-
ment antitumor T-cell response in both animal models 
and patients [16–19].
Despite growing attention, the immune responses 
induced by MWA in breast cancer are still unclear. The 
purpose of this study was to investigate the antitumor 
immunity against breast cancer induced by MWA and 




The murine breast cancer cell line 4T1 was obtained from 
Chinese Academy of Sciences (Shanghai, China). The 
cells were grown (37 °C incubator with 5% CO2) in RPMI 
1640 supplemented with 10% fetal bovine serum, 100 μg/
mL streptomycin, and 100  unit/mL penicillin. All cells 
culture reagents were purchased from Invitrogen (Shang-
hai, China).
Animal models
5 × 104 4T1 cells in 100 μL of PBS were injected subcuta-
neously into the right inguinal mammary fat pads of 6- to 
8-week-old female Balb/c mice (Vital River Laboratories, 
Beijing, China). The mice were euthanized when the 
tumor diameter exceeded 20  mm in diameter or when 
they became moribund during the observation period, 
and the time of euthanization was recorded as the time 
of mortality. All protocols and studies involving animals 
were approved by Nanjing Medical University Institu-
tional Animal Care and Use Committee.
Study design
Animals with established tumors were randomized 
to four groups. Mice in MWA group were treated with 
microwave ablation alone. About 30  min after MWA, 
1 Klinishe Einheit (KE; i.e., 0.1  mg) OK-432 (Lukang 
Pharmaceutical, Shandong, China) in 100  μL PBS were 
injected peritumorally in the combination treatment 
group, whereas mice treated with MWA alone were 
injected with 100 μL of PBS. The injection was repeated 
once 3 days later. Mice in OK-432 group received OK-432 
only. No-treatment group served as control.
For rechallenge test, mice that survived for 25  days 
after MWA and age-matched healthy mice were injected 
subcutaneously with 2 × 104 4T1 cells in 100 μL of PBS 
into the left inguinal mammary fat pads. Subsequently, 
the sizes of second tumors were measured with calipers 
every 5  days, and tumor volumes were calculated using 
the formula 1/2 (Length × Width2).
Microwave ablation
On day 35 after tumor implantation, when tumor size 
reached 8–10  mm in diameter, tumor-bearing mice 
were treated with MWA using a microwave generator 
(ECO-100E, Yigao Microwave Electric Institute, Nanjing, 
China). Mice were anesthetized with isoflurane (RWD 
Life Science, Shenzhen, China) inhalation. After disin-
fected the tumor area with alcohol, a 17-gauge MWA 
antenna (Yigao Microwave Electric Institute, Nanjing, 
China) was inserted into the center of the tumor. Accord-
ing to the results of the pre-test, MWA was performed 
at a power output of 5 W for 3 min to achieve complete 
ablation of primary tumors. The microwave irradiation 
frequency is 2450 MHz.
Immunohistochemical analysis
The removed tumor tissues were fixed in 4% formalin 
solution and paraffin embedded. Paraffin sections were 
stained with rat anti-mouse CD4 (4SM95, eBioscience, 
San Diego, USA) and rat anti-mouse CD8 (4SM15, eBi-
oscience) followed by horseradish peroxidase (HRP)-
conjugated goat anti-rat IgG (Santa Cruz Biotechnology, 
Santa Cruz, USA) and diaminobenzidine visualization 
(DAB kit, Beyotime, Nanjing, China). Nuclei were coun-
terstained with hematoxylin. The numbers of positive 
cells were counted in five randomly selected fields at 400-
fold magnification. Results from the five areas were aver-
aged and used in the statistical analysis.
Flow cytometric analysis
The harvested spleen was minced gently with the plunger 
of a 10  mL syringe and passed through a 70-μm nylon 
mesh cell strainer (Falcon, New Jersey, USA) to achieve 
a single cell suspension. Red blood cells were removed 
by cell lysis buffer (BD Biosciences, San Jose, USA). For 
intracellular cytokine staining, harvested cells were stim-
ulated with phorbol myristate acetate (PMA), ionomy-
cin, and brefeldin A (Cell Activation Cocktail, Biolegend, 
San Diego, USA) for 5 h. FITC-anti-CD4 (RM4-5), APC/
Cy7-anti-CD8a (53-6.7), and matched isotype control 
antibodies were purchased from BD Biosciences. PerCP/
Cy5.5-anti-CD4 (RM4-5), FITC-anti-IFN-γ (XMG1.2), 
APC-anti- interleukin (IL)-4 (11B11), and matched 
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isotype control antibodies were purchased from Biole-
gend. Flow cytometric analysis was performed using a 
FACS flow cytometer (Beckman Coulter, Miami, USA), 
and analyzed by Kaluza software (version: 1.1; Beckman 
Coulter).
ELISPOT assay
The enzyme-linked immunospot (ELISPOT) assays were 
performed with Mouse Interferon-γ (IFN-γ) ELISPOT 
Set (BD Biosciences) according to the manufacturer’s 
manual. Splenocytes (5  ×  105 cells/well) were added 
to plates precoated with anti-mouse IFN-γ antibody 
together with Mitomycin C treated 4T1 or CT26 cells 
(2.5  ×  105 cells/well). After cultured at 37  °C with 5% 
CO2 for 48 h, the plates were washed, further incubated 
with biotinylated detection antibody. Finally, the IFN-γ 
producing cells were visualized using AEC substrate set 
(BD Biosciences). The numbers of spots were counted 
automatically by BioSys BioReader 4000 PRO (Biosys, 
Karben, Germany).
ELISA assay
Blood was collected via cardiac puncture into tubes con-
taining EDTA. Plasma was obtained by centrifugation 
at 1000g for 10 min and stored at −70 °C until analysis. 
Concentrations of IL-2, IL-4, IL-10 and IFN-γ in plasma 
were measured by enzyme-linked immunosorbent assay 
(ELISA) using High Sensitivity ELISA Kit (eBiosciences). 
IL-12p70 and IL-18 were quantified using mouse IL-
12p70 Quantikine Reagent Kit (R & D Systems, Minneap-
olis, USA) and IL-18 Platinum ELISA Kit (eBiosciences) 
respectively.
Statistical analysis
The significance of differences between four experimen-
tal groups was assessed by one-way ANOVA followed 
by Student’s t-test with Bonferroni’s correction or Dun-
nett’s test for multiple comparisons. Student’s t-test was 
used for rechallenge test. Survival was analysed with the 
Kaplan–Meyer method comparing survival curves by 
log-rank test. Analyses were done with SPSS software 
(version: 22; SPSS, Chicago, USA). A P value of less than 
0.05 was considered statistically significant.
Results
Combination of MWA and OK‑432 resulted in prolonged 
survival and enough immunity against tumor rechallenge
To assess the antitumor effect of MWA, OK-432 and 
their combination in breast cancer, their abilities to pro-
mote survival were compared. Mice implanted ortho-
topically with 4T1 cells were treated with MWA, OK-432, 
the combination of MWA and OK-432 or left without 
treatment. Survival prolongation was observed in MWA 
treated mice, when compared with mice in OK-432 
group and untreated group (P = 0.006 and 0.001, respec-
tively, Fig. 1a), but there was no significant difference in 
survival between untreated group and OK-432 group. In 
the combination treatment group, survival was signifi-
cantly longer than that of MWA, OK-432 and untreated 
groups (all P < 0.001).
To simulate a clinical recurrence in patients, mice that 
survived for 25 days after treatment (MWA group: n = 3; 
MWA plus OK-432 group: n = 8) received reimplantation 
with 2 × 104 4T1 cells on the opposite flank. At 10 days 
after rechallenge, six MWA plus OK-432 treated mice 
still survivedto allow the evaluation of second tumor, 
while no mice survived in MWA alone group. Therefore, 
these survived mice from the combination treatment 
group (n = 6) were allocated to experimental group and 
age-matched healthy mice (n = 5) were used as controls. 
The combination therapy led to complete rejection of the 
second tumor in 83% (5/6) mice, while all control mice 
developed palpable tumors after implantation (Fig.  1b). 
These results indicate that MWA combined with OK-432 
prolongs survival, and induces enough antitumor immu-
nity that results in the rejection of rechallenged tumors.
Local administration of OK‑432 promoted CTL, but not Th 
cell infiltration into MWA treated tumors
Given the capacity of OK-432 to activate T-cell 
responses, the intratumoral infiltrations of CD4+ T 
helper (Th) cell and CD8+ cytotoxic T lymphocyte 
(CTL) were evaluated by immunohistochemistry on day 
7 after ablation. The number of intratumoral CD4+ T 
cells was significantly higher in MWA alone and MWA 
plus OK-432 groups than in no-treatment group (both 
P  <  0.001, Fig.  2b). OK-432 administration showed no 
impact on CD4+ T-cell infiltration into MWA treated 
or untreated tumors. Either MWA or OK-432 alone 
increased the number of CD8+ T cells infiltrating into 
the tumors compared with the numbers of these cells 
infiltrating into untreated tumors (P < 0.001 and =0.001, 
respectively, Fig.  2c). Moreover, the combination of 
MWA and OK-432 further enhanced CD8+ T-cell infil-
tration into tumors compared with tumors treated with 
single treatments (both P < 0.001). These results suggest 
that OK-432 enhances CTL but not Th cell infiltration 
induced by MWA.
OK‑432 augmented systemic T‑cell immune responses 
induced by MWA
To determine the impact of MWA combined with 
OK-432 on peripheral lymphocytes, the levels of CD4+ 
and CD8+ T cells in the spleen were analyzed by flow 
cytometry. On day 7 after ablation, the percentage of 
splenic CD4+ and CD8+ T cells of mice treated with 
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MWA alone were significantly increased when com-
pared with those of untreated mice (P  =  0.004 and 
<0.001, respectively, Fig. 3a, b). Subsequent administra-
tion of OK-432 after MWA further increased the lev-
els of CD4+ and CD8+ T cells in the spleen compared 
with those of MWA alone treated mice (P  =  0.011 
and =0.004, respectively). However, the proportion of 
splenic CD4+ and CD8+ T cells in MWA plus OK-432 
group was at similar level to that in MWA alone group 
14 days after ablation (data not shown). These data indi-
cate that MWA either alone or in combination with 
OK-432 induce systemic T-cell responses. The immune 
responses induced by MWA can be further enhanced by 
OK-432.
MWA and OK‑432 synergistically induced specific 
antitumor immunity
To further evaluate the specificity of immune response 
induced by treatments, IFN-γ ELISPOT assays were 
performed using splenocytes from mice 7  days after 
ablation. As shown in Fig.  4, the number of 4T1 spe-
cific IFN-γ secreting cells was 4- to 5- fold higher in 
MWA plus OK-432 treated mice compared with that in 
untreated mice (P < 0.001), while the effect of MWA or 
OK-432 alone did not meet a significant level of different 
values compared with no-treatment. The combination 
treatment group also had higher number of 4T1 specific 
IFN-γ secreting cells compared with MWA or OK-432 
alone groups (P  =  0.031 and <0.001, respectively). 
When the splenocytes stimulated with irrelevant CT26 
colon cancer cells, there was no significant difference 
between groups. These results indicate that MWA and 
OK-432 can synergistically elicit tumor-specific immune 
responses.
Treatment with MWA plus OK‑432 resulted in Th1 
dominant immunity
Since either OK-432 or thermal ablation has been 
reported to induce Th1 but not Th2-type immune 
response [14, 15, 20]. We hypothesized that MWA plus 
OK-432 would synergistically polarized Th1/Th2 balance 
to Th1 dominance. To prove this point, Th1 and Th2-
type responses were evaluated according to the produc-
tion of cytokines by CD4+ T cells on day 7 after ablation. 
MWA plus OK-432 treated mice had higher percentage 
of IFN-γ producing Th1 cells in the spleen compared 
with MWA or OK-432 alone treated mice (P = 0.004 and 
<0.001, respectively, Fig. 5a, b). In contrast, the percent-
age of IL-4 producing Th2 cells was lower in the combi-
nation treatment group compared with untreated group 
(P =  0.05, Fig.  5a, c). Neither MWA nor OK-432 alone 
affected Th1 or Th2 cell polarization. Therefore, the com-
bination treatment group showed markedly increased 
Th1 to Th2 ratio compared with MWA or OK-432 alone 
groups (P  =  0.022 and <0.001, respectively, Fig.  5d). 
These data suggest that although MWA with/without 
OK-432 enhance CD4+ Th cell response, only the com-
bination of MWA and OK-432 can induce a shift of Th1/
Th2 balance toward Th1 dominant state.
Induction of Th1‑type cytokines by OK‑432 administration 
after MWA
To further evaluated the levels of Th1 and Th2 related 
cytokines, plasma concentrations of multiple cytokines 
were measured as indicated. The levels of pro-inflam-
matory Th1-type cytokines IL-18 and IL-2 in MWA 
plus OK-432 group were significantly higher than those 
in MWA, OK-432 and no-treatment groups (IL-18: 
P = 0.007, 0.005, and 0.005, respectively; IL-2: P = 0.027, 
Fig. 1 OK-432 enhanced antitumor effects after MWA. a Kaplan-Meier curves showing survival of untreated mice and mice treated with OK-432, 
MWA, and MWA plus OK-432. For the rechallenge test, 2 × 104 4T1 cells were injected into left inguinal mammary fat pads of surviving mice on day 
25 after MWA. Age-matched healthy mice served as control (n = 5). b Tumor volumes of mice that survived over 10 days after rechallenge were 
calculated every 5 days (Experimental group: n = 6; Control group: n = 5). On day 25 after rechallenge, 5/5 of control mice and 1/6 of MWA plus 
OK-432 treated mice developed tumors after rechallenge. Points, mean; error bars, SEM. *P < 0.05; ***P < 0.001. One representative experiment out 
of three is shown
Page 5 of 10Li et al. J Transl Med  (2017) 15:23 
<0.001, and <0.001, respectively; Fig. 6b, d). Another Th1 
related cytokine IL-12 was upregulated in MWA alone 
treated mice compared to untreated mice (P = 0.033, 
Fig. 6a) and it was further enhanced by combining with 
OK-432 (P = 0.008). In addition, IFN-γ concentration in 
the combination treatment group was higher than those 
in OK-432 alone and no-treatment groups (P  =  0.010 
and 0.013, respectively, Fig.  6c). Interestingly, OK-432 
alone elevated the anti-inflammatory Th2-type cytokine 
IL-10, which was reduced when combined with MWA 
(P = 0.033, Fig. 6f ). Plasma level of IL-4 was not signifi-
cantly affected by any of these treatments (Fig. 6e). These 
data indicate that the combination treatment enhance 
the production of Th1-type but not Th2-type cytokines.
Discussion
As a minimally invasive technique, MWA of breast can-
cer may achieve complete tumor ablation with less sur-
gical complications, better cosmetic outcomes, shorter 
recovery times, and reduced health-care costs [1]. Our 
prior study has shown that MWA was a feasible approach 
for small breast cancer [7]. In addition to hyperthermic 
injury, the immunological effect induced by thermal abla-
tion may contribute another mechanism of tumor cell 
death and destruction [1].
During tumor destruction caused by thermal ablation, 
intracellular tumor-specific antigens are released and 
captured by antigen-presenting cells in lymphatic tissue 
[8, 21]. These antigens are processed and presented to 
T cells to activate antitumor immunity [22, 23]. Recent 
research has shown that both local and systemic T-cell 
responses were elicited by MWA alone in hepatoma 
and osteosarcoma [9, 10]. Although MWA induced 
T-cell responses in breast cancer were firstly reported 
by us, the median survival of MWA treated mice was 
only 5  days longer than that of untreated mice. Previ-
ous study has reported that T-cell response induced by 
MWA is not enough to protect patients from relapse, 
Fig. 2 OK-432 increased infiltration of cytotoxic CD8+ T-cell into tumors after MWA. a representative microphotographs of CD4 and CD8 staining in 
each group. Immunohistochemical staining was performed on tumor specimens that were harvested 7 days after treatment. Original magnification, 
×400. Bar, 50 μm. b, c Density of CD4+ and CD8+ cells was determined. Five random areas within a section were chosen and counted at 400-fold 
magnification. Columns, mean; error bar, SEM. ***P < 0.001. Data were pooled from two independent experiments with five mice per group
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Fig. 3 The combination of MWA and OK-432 augmented systemic T-cell responses. Mononuclear cells were prepared from spleen and used for 
flow cytometric analysis. a Representative flow cytometric plots showing CD4+ and CD8+cells on days 7 after MWA. b Percentage of CD4+ and 
CD8+ cells in splenocytes on days 7 after MWA. Column, mean; error bars, SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS not significant. Data were 
pooled from two independent experiments with six mice per group
Fig. 4 MWA plus OK-432 activated systemic tumor-specific immune responses. IFN-γ secreting cells were analyzed by ELISPOT. Mononuclear cells 
were prepared from spleen and cultured with 4T1 or CT26 cells for 48 h. a Representative ELISPOT images from each group. b the ELIPSOT count in 
each group. Column, mean; error bars, SEM. *P < 0.05; ***P < 0.001; NS not significant. Data were pooled from two independent experiments with 
eight mice per group
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while immunocyte infiltration extent in ablated tissue is 
inversely correlated with overall survival and local recur-
rence rate [10]. Thus, combining MWA with immune 
adjuvants to enhance antitumor immune response may 
achieve additional clinical benefit.
Several studies have explored the combination strate-
gies to augment antitumor immunity by administration 
of immunostimulant, such as IL-2, IFN-β, and staphylo-
coccal enterotoxin C (SEC) [24–26]. Nevertheless, these 
adjuvants are still under preclinical development. In con-
trast, OK-432 has been used as immuno-oncology agents 
in clinical practice for over 40 years [13]. Previous studies 
have reported the ability of OK-432 to improve the sur-
vival of patients after resection of lung or gastric cancers 
Fig. 5 MWA plus OK-432 polarized T-cell responses to Th1 dominance. Mononuclear cells were prepared from spleen and stimulated with PMA, 
ionomycin, and brefeldin A for 5 h before flow cytometric analysis. a Representative flow cytometric plots showing CD4+ IFN-γ+ and CD4+ IL-4+ 
cells on days 7 after MWA. b, c, the percentage of IFN-γ secreting Th1 and IL-4 secreting Th2 cells in CD4+ Th cells. d The ratio of Th1 to Th2 cells was 
calculated for each mouse. Column, mean; error bars, SEM. *P < 0.05; **P < 0.01; ***P < 0.001. Data were pooled from two independent experiments 
with five mice per group
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[27, 28]. Our data showed that local injection of OK-432 
after MWA markedly prolonged the survival of mice and 
protected most surviving mice from tumor rechallenge, 
suggesting that this combination therapy could provide 
augmented clinical benefit and may prevent tumor recur-
rence. Similar to the results of Behm et al and Iida et al 
who used RFA in animal models [20, 29], we observed 
increased number of T cells infiltrated into ablated tis-
sues. Moreover, we showed that OK-432 could further 
enhance CTL rather than Th cell infiltration that induced 
by MWA. In addition, our findings showed that OK-432 
plus MWA not only promote peripheral T-cell responses, 
but also synergistically elicit systemic tumor-specific 
immunity. This augmented antitumor immunity might 
result in the tumor rejection in rechallenge test.
Next, we explored the role of CD4+ Th cell upon this 
synergistic effect on immune system. Th cell can be clas-
sified generally into two predominant subtypes as Th1 
and Th2 cell, which can cross-inhibit each other [30]. 
Although Th2 cell has been reported to promote the 
recruitment of eosinophils and macrophages into the 
tumor microenvironment [31], it appears to contribute 
to tumor progression in another research [32]. On the 
other hand, Th1 cell promotes durable tumor-specific 
CTL responses and induces strong immunological mem-
ory against tumor rechallenge [31, 33]. In this study, we 
found that Th1 to Th2 ratio in the combination treatment 
group was significantly higher than that of other groups. 
These data may suggest that skewing of Th1/Th2 balance 
toward Th1-dominated immunity is responsible for the 
augmented T-cell responses that observed in the combi-
nation treatment group. Additional, plasma levels of Th1-
type cytokines, including IL-12, IL-18, IL-2, and IFN-γ, 
were increased in mice treated with MWA plus OK-432, 
whereas Th2-type cytokines were not affected. As previ-
ously mentioned, OK-432 could augment the production 
of IL-12 and IL-18 [14, 15]. These two cytokines were 
shown to synergistically induce T cells to differentiate 
into Th1 cells [34, 35], and stimulate IFN-γ production 
from Th1 cells [36]. Th1 cell secreting IL-2 is crucial to 
the expansion of CD8+ T cells and is particularly impor-
tant for the functional maturation of activated T cells [37, 
38]. These results may indicate that combining OK-432 
with MWA could produce various Th1-type cytokines 
Fig. 6 MWA combined with OK-432 induced Th1-type but not Th2-type cytokines. Blood was collected on day 7 after MWA and plasma was iso-
lated as indicated. Levels of cytokines were measured by ELISA. a–f Plasma concentrations of IL-12p70, IL-18, IFN-γ, IL-2, IL-4, and IL-10 in each group. 
Column, mean; error bars, SEM. *P < 0.05; **P < 0.01; ***P < 0.001; NS not significant. Data were pooled from two independent experiments with six 
or seven mice per group
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to activate Th1-type response, and this process might be 
potentially an important mechanism underlying the syn-
ergistic effect of this combination therapy.
Several limitations in our study should be noted. First, 
the optimal dose or schedule of OK-432 has yet to be 
determined. Based on the data from previous animal 
experiments [39], mice in our study received two doses 
of OK-432 (1 KE per mouse) given 3 days apart. However, 
the synergistic effect on Th cell was not observed 14 days 
after MWA. Thus, a longer duration of OK-432 treatment 
might provide greater therapeutic benefits. Second, the 
progression and immune responses in metastatic lesions 
were not evaluated when primary tumors were ablated. 
Moreover, the antitumor effects of Th cell and CTL could 
be further demonstrated through additional experi-
ments, such as CD4+ or CD8+ T cell depletion. Also, the 
changes in regulatory T cell and myeloid-derived sup-
pressor cell were not examined to determine whether 
MWA affects the tumor immunosuppressive environ-
ments. Finally, antitumor immunity may vary widely with 
different tumor host systems. Thus, the immunological 
effect of MWA and OK-432 should be validated in other 
animal models and humans.
In conclusion, the present study showed that MWA in 
breast cancer could elicit T-cell infiltration and systemic 
T-cell responses. Subsequent administration of OK-432 
induced multiple Th1-type cytokines and polarized T-cell 
responses to Th1 dominance. Furthermore, the combina-
tion treatment augmented both local and systemic T-cell 
responses, and synergistically elicited strong tumor-spe-
cific immune responses. Lastly, MWA plus OK-432 pro-
longed the survival of 4T1 breast cancer bearing mice 
and resulted in complete rejection of tumor rechallenge 
in most surviving animals. These data together indicate 
that the combination of OK-432 and MWA is a potent 
activator of antitumor immunity. Considering the fea-
sibility and efficiency of either MWA or OK-432 in the 
treatment of tumors [6, 7, 28], this combination offers a 
novel treatment option for breast cancer.
Conclusions
Thermal ablation was previously reported to elicit antitu-
mor immunity in several solid tumors, but little is known 
about the immunomodulation activated by microwave 
ablation in breast cancer. In this study, we showed that 
T-cell responses was induced by microwave ablation 
in a murine breast cancer model, and the combination 
of microwave ablation and immunostimulant OK-432 
synergistically polarized the T-cell responses to Th1 
dominance and augmented specific antitumor immu-
nity. Considering the feasibility and efficiency of either 
MWA or OK-432 in the treatment of solid tumors, the 
combination of microwave ablation and OK-432 might 
be a promising treatment option for breast cancer.
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